Thursday 25th February 2021 |
Text too small? |
In November 2020 Gentrack Group Limited (NZX/ASX: GTK) (“Gentrack”) advised that it expected that the full year EBITDA run rate for FY21 would be well below that of the H2 FY20 run rate and that FY21 profitability may be reduced closer to break-even depending on the levels of future product investment and other factors.
Gentrack now provides the following outlook update:
•FY21 revenues are expected to be close to or slightly ahead of FY20 revenues of $100.5m
•FY21 EBITDA is expected to be around $5m on the basis that research and development (R&D) costs are expensed
•Incremental R&D costs are expected to be ~$3m/quarter from Q3 FY21
•The company expects to be net cashflow positive in FY21, building on the $16.8m of net cash reported at 30th September 2020.
Profit and cashflow are expected to be weighted to H1 FY21 given the incremental R&D spend forecast for H2.
Please see the link below for details:
Source: Gentrack Group Limited
No comments yet
NZAS Sign Long Term Contracts
Amended - IFT230 Maturity and Exchange for IFT350
Synlait forecast milk price update
Chorus submits 2023 fibre regulatory report
Infratil Infrastructure Bond Exchange Offer opens
May 31st Morning Report
NZAS and Mercury sign long-term agreement, creating opportunity for future investment in renewables
Meridian and NZAS sign long term contracts
ArborGen Holdings Results for Year Ended 31 March 2024
BAI - Full unaudited results to 31 March 2024